PPOX
protein-codingprotoporphyrinogen oxidase
Gene summary
This gene encodes the penultimate enzyme of heme biosynthesis, which catalyzes the 6-electron oxidation of protoporphyrinogen IX to form protoporphyrin IX. Mutations in this gene cause variegate porphyria, an autosomal dominant disorder of heme metabolism resulting from a deficiency in protoporphyrinogen oxidase, an enzyme located on the inner mitochondrial membrane. Alternatively spliced transcript variants encoding the same protein have been identified. [provided by RefSeq, Jul 2008]
- VP
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~12.0 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AD
Disease ID:MONDO:0008297
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: SD
Disease ID:MONDO:0008297
Submitter: ClinGen
The gene *PPOX* has been strongly associated with the disease variegate porphyria according to the gene-disease association criteria of the ACMG (SOP version 10). Previously, variegate porphyria was reported as two disease entities with differing modes of inheritance (autosomal recessive and autosomal dominant) (OMIM). Other papers have discussed the disease as autosomal dominant with incomplete penetrance (PMID: 29516370; 10870850). However, based on ACMG lumping and splitting criteria, variegate porphyria has been reclassified as semidominant due to its consistent molecular mechanism of disease and due to the observation that missense mutations that preserve 10–25% of PPOX activity may not cause clinically overt disease (PMID: 9811936). Homozygous or biallelic pathogenic mutations, which severely reduce enzyme activity (<25% of normal), typically result in symptoms beginning before puberty. The reported symptoms include abnormal blistering of the skin, photosensitivity, brachydactyly, short stature, nystagmus, myopia, sensory neuropathy, intellectual disability, respiratory paralysis, and abnormal circulating porphyrin concentration in plasma, urine, and stool. Individuals who are heterozygous for pathogenic mutations are at risk for an acute attack, usually presenting with abdominal pain, post puberty onset of photosensitivity, or both. The accumulation of neurotoxic porphyrin precursors such as 5-aminolevulinic acid (ALA) and porphobilinogen (PBG), which are linear non-fluorescent molecules, is observed during acute attacks (PMID: 29516370). The accumulation of protoporphyrins, which are circular molecules that emit fluorescence when excited, is responsible for causing cutaneous photosensitivity. Although this disease has been categorized as one of the acute porphyrias, not all affected individuals experience acute attacks. Instead, symptoms are consistent with a spectrum of disease that worsens with lower enzyme activity and for which porphyrogenic agents (e.g. certain drugs, alcohol, low-carb diets, etc.) can induce an attack. The gene *PPOX* encodes the enzyme protoporphyrinogen oxidase, which converts protoporphyrinogen-IX to protoporphyrin-IX. This enzyme is localized to the mitochondria and requires the cofactor FAD (vitamin B2). The protein primarily exists in vitro as a monomer but is expected to dimerize in vivo. Observed variegate porphyria mutations have been mapped to the PPOX structure and separated into the following different categories: affecting FAD binding (R59W, G11D, G11S, L15F, H20P, E34V, G40E, G40A, G232R, G232S, D349A, S350P, G448R, S450P, G453V, G453R), affecting substrate binding (R168H, R168C, G169E, A172V, G330R, G332A, V335G, Y348C, L401F), affecting the hydrophobic core (I12T, V84G, W224G and W224R, L236S, V282D, I283N, and A397D), affecting protein surface interactions (R38P, H106P, R138P, D143V, R152C, and R217C), and affecting protein secondary structure (L295, L444) (PMID: 21048046). Summary of Case Level Data (10.8 points): 12 probands were scored with 14 unique variants (three nonsense and eleven missense variants). Summary of Experimental Evidence (2 points): Biochemical characterization of the enzymatic reaction where purified WT and mutant protoporphyrinogen oxidase activity was assayed by measuring the velocity of the formation of protoporphyrin from protoporphyrinogen was scored. The high resolution crystal structure was also scored. In summary, *PPOX* has been strongly associated with the semidominant condition, variegate porphyria.
Inheritance Pattern: AR
Disease ID:MONDO:0008297
Submitter: Genomics England PanelApp
Inheritance Pattern: SD
Disease ID:MONDO:0008297
Submitter: Ambry Genetics
Inheritance Pattern: AD
Disease ID:MONDO:0008297
Submitter: Genomics England PanelApp
Inheritance Pattern: AR
Disease ID:MONDO:0957577
Submitter: PanelApp Australia
Inheritance Pattern: AD
Disease ID:MONDO:0008297
Submitter: Orphanet
Inheritance Pattern: AD
Disease ID:MONDO:0008297
Submitter: PanelApp Australia
Clinical Genomic Database (CGD)
Manifestation: Biochemical; Dermatologic; Musculoskeletal; Neurologic; Renal
Intervention: Dermatologic; Pharmacogenomic
Rationale: Acute attacks may be precipitated by porphyrinogenic agents, which, along with other exacerbating factors, should be avoided; Skin protection is warranted
Comments: Homozygosity/compound heterozygosity results in a distinct and much more severe phenotype
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to PPOX variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_001122764.3. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 1 | 6 | 42 | 1 | 50 | |
| missense | 12 | 9 | 146 | 9 | 1 | 177 |
| nonsense | 12 | 4 | 16 | |||
| start loss | 1 | 1 | ||||
| frameshift | 12 | 9 | 1 | 22 | ||
| splice donor/acceptor (+/-2bp) | 6 | 9 | 5 | 20 | ||
| Total | 43 | 32 | 158 | 51 | 2 | 286 |
Highest pathogenic variant AF is 0.00011852949
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_001116236.1 | 12 | MANE Select | |
| Ensembl | ENSP00000356978.4 | 12 | MANE Select | |
| RefSeq | NP_000300.1 | 12 | Standard | |
| RefSeq | NP_001337057.1 | 11 | Standard |
Model Organisms & Knockout Phenotypes
Observed phenotypic effects in mouse and zebrafish models
| Gene / Model | Organism | Observed Phenotype |
|---|---|---|
| ppox | Danio rerio | Structure: nucleate erythrocyte Quality: decreased amount abnormal |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Porphyrin and chlorophyll metabolism - Homo sapiens (human)
- Hereditary Coproporphyria (HCP)
- Porphyria Variegata (PV)
- Congenital Erythropoietic Porphyria (CEP) or Gunther Disease
- Acute Intermittent Porphyria
Biological Process
- porphyrin-containing compound biosynthetic process
- protoporphyrinogen IX biosynthetic process
- heme biosynthetic process
- response to drug
- oxidation-reduction process
Molecular Function
- oxygen-dependent protoporphyrinogen oxidase activity
- oxidoreductase activity
- flavin adenine dinucleotide binding
Cellular Component
- mitochondrion
- mitochondrial intermembrane space
- intrinsic component of mitochondrial inner membrane
- integral component of mitochondrial inner membrane
- mitochondrial membrane
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000367999
- Coding exons
- 12
- Length
- 11604
- Individuals with no LoFs
- 125730
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 18
- Defined
- 125748
- p
- 0.0000716
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 0.975 | 216 | 260 | 0.830 | 0.0000155 | 3005 |
| Missense (PolyPhen) | 60 | 96.147 | 0.62404 | 1153 | ||
| Synonymous | -0.431 | 108 | 102 | 1.05 | 0.00000542 | 1065 |
| Loss of Function | 3.09 | 7 | 23.0 | 0.305 | 0.00000103 | 274 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.000062 | 0.000062 | rare |
| Latino/Admixed American | 0 | 0.0 | absent |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0.000054 | 0.000054 | rare |
| Finnish | 0 | 0.0 | absent |
| European (Non-Finnish) | 0.00012 | 0.00012 | rare |
| South Asian | 0.000033 | 0.000033 | rare |
| Other | 0.00016 | 0.00016 | rare |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Catalyzes the 6-electron oxidation of protoporphyrinogen-IX to form protoporphyrin-IX. {ECO:0000269|PubMed:21048046, ECO:0000269|PubMed:23467411, ECO:0000269|PubMed:7713909}.;
Recessive Scores
- pRec
- 0.297
Intolerance Scores
- LoFtool
- 0.0727
- RVIS EVS
- -0.25
- RVIS percentile EVS
- 35.99
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Essential (gene trap)
- N
- Indispensability pred.
- E
- Indispensability score
- 0.999
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |